These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28140756)

  • 1. How to "PrEP" for HIV Prevention in Women.
    Ntim GJ; Kransdorf LN
    J Womens Health (Larchmt); 2017 Feb; 26(2):195-196. PubMed ID: 28140756
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet.
    Wang X; Nutland W; Brady M; Green I; Boffito M; McClure M
    Int J STD AIDS; 2019 Jul; 30(8):765-768. PubMed ID: 31072205
    [No Abstract]   [Full Text] [Related]  

  • 3. Better late than never: PrEP in England.
    The Lancet Hiv
    Lancet HIV; 2017 Jan; 4(1):e1. PubMed ID: 28007341
    [No Abstract]   [Full Text] [Related]  

  • 4. Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(6):520. PubMed ID: 26977839
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is sub-Saharan Africa ready for pre-exposure prophylaxis?
    Bernier A; Gapiya J; Sylla A; Anoma C; Somda M; Dah E; Aranda JF; Himmich H
    Lancet HIV; 2016 Apr; 3(4):e154-5. PubMed ID: 27036989
    [No Abstract]   [Full Text] [Related]  

  • 7. Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows.
    Mayor S
    BMJ; 2015 Sep; 351():h4860. PubMed ID: 26359448
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV Prevention: Opportunities and Challenges.
    Marrazzo JM
    Top Antivir Med; 2017; 24(4):123-126. PubMed ID: 28208119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
    AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention.
    Rowan SE; Patel RR; Schneider JA; Smith DK
    Lancet HIV; 2021 Feb; 8(2):e114-e120. PubMed ID: 33128874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual HIV pre-exposure prophylaxis outpatient service in the era of COVID-19.
    Quirke S; Quinn L; Hegarty D; Loy A; Lyons F; Mulcahy F; Devitt E
    Int J STD AIDS; 2021 Jan; 32(1):100-103. PubMed ID: 33050787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis.
    Jewsbury S; Ward C
    Int J STD AIDS; 2020 Jan; 31(1):85-87. PubMed ID: 31801029
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK; Baeten JM
    Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group.
    Balayan T; Begovac J; Skrzat-Klapaczyńska A; Aho I; Alexiev I; Bukovinova P; Salemovic D; Gokengin D; Harxhi A; Holban T; Jevtovic D; Kase K; Lakatos B; Latysheva I; Matulionyte R; Oprea C; Papadopoulos A; Rukhadze N; Sedlacek D; Tomazic J; Vassilenko A; Vasylyev M; Verhaz A; Yancheva N; Yurin O; Horban A; Kowalska JD;
    HIV Med; 2021 Jan; 22(1):67-72. PubMed ID: 33021049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UK PrEP decision re-ignites HIV activism.
    The Lancet
    Lancet; 2016 Apr; 387(10027):1484. PubMed ID: 27115959
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.
    Baker J; OʼHara KM
    JAAPA; 2014 Dec; 27(12):10-7. PubMed ID: 25390822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities.
    Girometti N; Jones R; Levy J; McCormack S; Sullivan A; Barber TJ
    AIDS; 2016 Aug; 30(13):2131-3. PubMed ID: 27219131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.
    Dunn DT; Glidden DV; Stirrup OT; McCormack S
    Lancet HIV; 2018 Jun; 5(6):e329-e334. PubMed ID: 29893246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
    Carballo-Diéguez A; Giguere R; Dolezal C; Leu CS; Balán IC; Brown W; Rael C; Richardson BA; Piper JM; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla CD; Lama JR; McGowan I; Cranston RD;
    AIDS Behav; 2017 Dec; 21(12):3336-3345. PubMed ID: 29119473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.